Jump to content

Abexinostat

From Wikipedia, the free encyclopedia
Abexinostat
Names
IUPAC name
3-[(Dimethylamino)methyl]-N-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide
Other names
PCI-24781; CRA-024781
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.241.399 Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25) checkY
    Key: MAUCONCHVWBMHK-UHFFFAOYSA-N checkY
  • InChI=1/C21H23N3O5/c1-24(2)13-17-16-5-3-4-6-18(16)29-19(17)21(26)22-11-12-28-15-9-7-14(8-10-15)20(25)23-27/h3-10,27H,11-13H2,1-2H3,(H,22,26)(H,23,25)
    Key: MAUCONCHVWBMHK-UHFFFAOYAM
  • O=C(NO)c3ccc(OCCNC(=O)c2oc1ccccc1c2CN(C)C)cc3
Properties
C21H23N3O5
Molar mass 397.431 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Abexinostat (INN,[1] formerly PCI-24781) is an experimental drug candidate for cancer treatment.[2] It was developed by Pharmacyclics and licensed to Xynomic. As of 2013, it was in Phase II clinical trials for B-cell lymphoma.[3][needs update] Pre-clinical study suggests the potential for treatment of different types of cancer as well.[4][5][6][7]

Abexinostat exerts its effect as a pan-histone deacetylase inhibitor[8][9] and inhibits RAD51, which is involved in repairing DNA double strand breaks.[10]

Progress

[edit]

Abexinostat has been granted a fast track designation by the FDA for the treatment of patients with relapsed or refractory follicular lymphoma in the fourth-line setting. This designation is significant as it aims to expedite the development and review of drugs intended to treat serious conditions and fill an unmet medical need.

Research

[edit]

The FORERUNNER conducted a study, a potentially pivotal phase II trial of abexinostat monotherapy in patients with relapsed/refractory follicular lymphoma, in the United States and Europe.[11] In the phase II study, abexinostat showed a modest overall response rate (ORR) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with a notably higher ORR observed in patients with follicular lymphoma. This study involved 100 patients treated with 80 mg of abexinostat twice daily for 14 days of a 21-day cycle. The ORR for follicular lymphoma specifically was 56%, indicating a significant impact on this lymphoma subtype. The study also reported grade ≥3 adverse events in a considerable number of patients, with thrombocytopenia, neutropenia, and anemia being the most frequently reported.[11]

Safety and efficacy

[edit]

Abexinostat has been characterized by its unique pharmacokinetic profile and oral dosing schedule, allowing for continuous exposure at concentrations required for efficient tumor cell killing. [12]

References

[edit]
  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). 2011.
  2. ^ "Abexinostat". NCI Cancer Dictionary.
  3. ^ "Abexinostat HCl (PCI-24781), PanHDAC-inhibitor". Pharmacyclics. Archived from the original on 2013-10-27.
  4. ^ Bhalla, S; Balasubramanian, S; David, K; Sirisawad, M; Buggy, J; Mauro, L; Prachand, S; Miller, R; Gordon, LI; Evens, AM (2009). "PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells". Clinical Cancer Research. 15 (10): 3354–65. doi:10.1158/1078-0432.CCR-08-2365. PMC 2704489. PMID 19417023.
  5. ^ Lopez, G; Liu, J; Ren, W; Wei, W; Wang, S; Lahat, G; Zhu, QS; Bornmann, WG; McConkey, DJ; Pollock, RE; Lev, DC (2009). "Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma". Clinical Cancer Research. 15 (10): 3472–83. doi:10.1158/1078-0432.CCR-08-2714. PMID 19417021. S2CID 18862692. (Erratum: doi:10.1158/1078-0432.CCR-15-0351, PMID 25833311. If the erratum has been checked and does not affect the cited material, please replace {{erratum|...}} with {{erratum|...|checked=yes}}.)
  6. ^ Rivera-Del Valle, N; Gao, S; Miller, CP; Fulbright, J; Gonzales, C; Sirisawad, M; Steggerda, S; Wheler, J; Balasubramanian, S; Chandra, J (2010). "PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells". International Journal of Cell Biology. 2010: 207420. doi:10.1155/2010/207420. PMC 2817379. PMID 20145726.
  7. ^ Yang, C; Choy, E; Hornicek, FJ; Wood, KB; Schwab, JH; Liu, X; Mankin, H; Duan, Z (2011). "Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells". Cancer Chemotherapy and Pharmacology. 67 (2): 439–46. doi:10.1007/s00280-010-1344-7. PMID 20461381. S2CID 1344662.
  8. ^ Buggy, JJ; Cao, ZA; Bass, KE; Verner, E; Balasubramanian, S; Liu, L; Schultz, BE; Young, PR; Dalrymple, SA (2006). "CRA-024781: A novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo". Molecular Cancer Therapeutics. 5 (5): 1309–17. doi:10.1158/1535-7163.MCT-05-0442. PMID 16731764.
  9. ^ Adimoolam, S; Sirisawad, M; Chen, J; Thiemann, P; Ford, JM; Buggy, JJ (2007). "HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination". Proceedings of the National Academy of Sciences of the United States of America. 104 (49): 19482–7. Bibcode:2007PNAS..10419482A. doi:10.1073/pnas.0707828104. PMC 2148315. PMID 18042714.
  10. ^ "NCI Drug Dictionary". National Cancer Institute.
  11. ^ a b "FDA Grants Fast Track Designation to Abexinostat for Fourth-Line Follicular Lymphoma". Targeted Oncology. 2019-09-23. Retrieved 2024-02-14.
  12. ^ Ribrag, Vincent; Kim, Won Seog; Bouabdallah, Reda; Lim, Soon Thye; Coiffier, Bertrand; Felloussi, Zakia; Kloos, Ioana; Luan, Ying; Graef, Thorsten; Morschhauser, Franck (2015-12-03). "Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study". Blood. 126 (23): 256. doi:10.1182/blood.V126.23.256.256. ISSN 0006-4971. Retrieved 2024-02-14.